Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
Real-time Estimate Cboe BZX  -  02:10 2022-11-28 pm EST
49.17 USD   -1.05%
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wedbush Maintains Forecast
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

09/21/2022 | 08:00am EST

Pacira BioSciences, Inc. announced positive topline results from its Phase 3 study of EXPAREL as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients undergoing bunionectomy. EXPAREL achieved the study's primary endpoint by demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl (p<0.00001). EXPAREL also achieved statistical significance for reduction in postsurgical opioid consumption (p<0.00001) and percentage of opioid-free subjects (p<0.001) through 96 hours compared with bupivacaine HCl, which were key secondary endpoints.

EXPAREL was well tolerated with a safety profile consistent with bupivacaine HCl. Pacira plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) early next year to expand the EXPAREL label to include sciatic nerve blocks in the popliteal fossa, as well as femoral nerve blocks in the adductor canal. Earlier this month, Pacira announced positive results from a Phase 3 study of EXPAREL as a single-dose femoral nerve block in the adductor canal for total knee arthroplasty.

A sciatic nerve block in the popliteal fossa is used for anesthesia and analgesia for foot, ankle, achilles tendon, and other lower leg surgeries. A femoral nerve block in the adductor canal is used for anesthesia and analgesia for surgery of the knee, medial lower leg, and ankle surgeries.


ę S&P Capital IQ 2022
All news about PACIRA BIOSCIENCES, INC.
11/15Sector Update: Health Care Stocks Edge Higher Premarket Tuesday
MT
11/15Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October; Wed..
MT
11/14Pacira BioSciences Reports Higher Exparel Preliminary Net Product Sales in October
MT
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/14Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2..
GL
11/08Pacira BioSciences to Present at Two Healthcare Conferences in November
GL
11/07BMO Capital Adjusts Price Target on Pacira BioSciences to $60 From $66, Maintains Marke..
MT
11/04HC Wainwright Adjusts Price Target on Pacira BioSciences to $76 From $83, Maintains Buy..
MT
11/04RBC Trims Pacira BioSciences' Price Target to $80 From $82, Keeps Outperform Rating
MT
11/04Wedbush Lowers Pacira BioSciences' Price Target to $88 From $94, Keeps Outperform Ratin..
MT
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 677 M - -
Net income 2022 47,0 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 51,9x
Yield 2022 -
Capitalization 2 280 M 2 280 M -
EV / Sales 2022 4,12x
EV / Sales 2023 3,25x
Nbr of Employees 697
Free-Float 98,9%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 49,69 $
Average target price 73,55 $
Spread / Average Target 48,0%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-17.42%2 280
JOHNSON & JOHNSON3.61%463 391
ELI LILLY AND COMPANY32.23%347 052
ABBVIE INC.17.89%282 189
PFIZER, INC.-16.66%276 231
MERCK & CO., INC.40.27%272 555